Pathstone Family Office’s Oncorus, Inc. ONCR Stock Holding History

Pathstone Family Office’s Portfolio ONCR Stock Details ONCR Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q1	–	Sell	-202	Closed	-$7K	–	1419
2020 Q4	$7K	Buy	+202	New	+$4.68K	﹤0.01%	924

Other funds holding ONCR

Deerfield Management New York $9.59B AUM 113.36% 1-Year Est. Return

MPM Asset Management Boston, Massachusetts $44.5M AUM 47.28% 1-Year Est. Return

MPM BioImpact Boston, Massachusetts $1.64B AUM 245.64% 1-Year Est. Return

Perceptive Advisors New York $6.66B AUM 360.84% 1-Year Est. Return

Citadel Advisors

Citadel Advisors Miami, Florida $875B AUM 40.91% 1-Year Est. Return

CHI Advisors New York $252M AUM 56.99% 1-Year Est. Return

Fosun International Hong Kong, China $446M AUM 13.33% 1-Year Est. Return

Sphera Funds Management Tel Aviv, Israel $767M AUM 119.71% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Luminus Management Houston, Texas $146M AUM 27.83% 1-Year Est. Return

Pathstone Family Office's ONCR Position: Q1 2021 in Review

Pathstone Family Office sold out of Oncorus, Inc. (ONCR) in Q1 2021, closing a stake of 202 shares — an estimated $7K sold.

Pathstone Family Office first reported a position in ONCR in Q4 2020 and held it in 1 quarter. The position peaked at $7K in Q4 2020. 57 funds tracked by Wall St. Rank hold ONCR as of Q1 2021.

Pathstone Family Office reported no remaining Oncorus, Inc. position as of Q1 2021 after selling out during the quarter.
Pathstone Family Office sold 202 Oncorus, Inc. shares in Q1 2021, an estimated $7K.
Pathstone Family Office first reported a position in Oncorus, Inc. in Q4 2020 and held it in 1 quarter.
Pathstone Family Office's Oncorus, Inc. position peaked at $7K in Q4 2020.
57 funds tracked by Wall St. Rank held Oncorus, Inc. as of Q1 2021.

Based on Pathstone Family Office's 13F filing for Q1 2021, filed 14 May 2021.